The effects of caffeine supplementation on clinical parameters and disease severity in patients with hepatic cirrhosis
Phase 2
Recruiting
- Conditions
- Hepatic Cirrhosis.
- Registration Number
- IRCT20100524004010N34
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Having desire to participate in the study
Age range of 18-75
BMI between 18.5 to 30 kg per square meter
Do not develop extrahepatic organ failure
Do not take caffeinated drugs for one month before the start of the study
Do not consume more than 3 cups of coffee per day
Not pregnant or breastfeeding
Exclusion Criteria
The patient's unwillingness to continue cooperation
Patients who have consumed less than 80% of the capsules.
The diagnosis of the treating physician at the end of the patient's participation in the study
Pregnancy or breastfeeding
Loss of more than 10% of body weight during the study period
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Model for end-stage liver cirrhosis score (MELD score). Timepoint: At the beginning and the end of the study. Method of measurement: Using the formula.
- Secondary Outcome Measures
Name Time Method